SPDR S&P Biotech (XBI) is Crescent Grove Advisors LLC’s 8th Largest Position

Crescent Grove Advisors LLC boosted its holdings in SPDR S&P Biotech (NYSEARCA:XBI) by 4.5% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 91,980 shares of the exchange traded fund’s stock after buying an additional 3,948 shares during the quarter. SPDR S&P Biotech makes up about 2.0% of Crescent Grove Advisors LLC’s holdings, making the stock its 8th largest position. Crescent Grove Advisors LLC owned 0.18% of SPDR S&P Biotech worth $7,963,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of XBI. Raymond James Financial Services Advisors Inc. boosted its stake in SPDR S&P Biotech by 13.9% in the second quarter. Raymond James Financial Services Advisors Inc. now owns 240,709 shares of the exchange traded fund’s stock valued at $18,578,000 after acquiring an additional 29,346 shares in the last quarter. Newman Dignan & Sheerar Inc. boosted its stake in SPDR S&P Biotech by 0.6% in the second quarter. Newman Dignan & Sheerar Inc. now owns 8,260 shares of the exchange traded fund’s stock valued at $638,000 after acquiring an additional 50 shares in the last quarter. WealthPLAN Partners LLC boosted its stake in SPDR S&P Biotech by 1,107.2% in the second quarter. WealthPLAN Partners LLC now owns 10,527 shares of the exchange traded fund’s stock valued at $812,000 after acquiring an additional 9,655 shares in the last quarter. Cornerstone Advisory LLP boosted its stake in SPDR S&P Biotech by 109.0% in the second quarter. Cornerstone Advisory LLP now owns 14,628 shares of the exchange traded fund’s stock valued at $1,129,000 after acquiring an additional 7,628 shares in the last quarter. Finally, FineMark National Bank & Trust boosted its stake in SPDR S&P Biotech by 7.4% in the second quarter. FineMark National Bank & Trust now owns 5,210 shares of the exchange traded fund’s stock valued at $402,000 after acquiring an additional 360 shares in the last quarter.

TRADEMARK VIOLATION WARNING: This report was originally reported by Markets Daily and is owned by of Markets Daily. If you are accessing this report on another website, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The original version of this report can be viewed at https://www.themarketsdaily.com/2017/11/13/spdr-sp-biotech-xbi-is-crescent-grove-advisors-llcs-8th-largest-position.html.

SPDR S&P Biotech (NYSEARCA:XBI) traded down $0.15 during midday trading on Monday, reaching $82.77. 4,296,600 shares of the company’s stock traded hands, compared to its average volume of 4,219,603. SPDR S&P Biotech has a one year low of $58.66 and a one year high of $88.98.

SPDR S&P Biotech Company Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech (NYSEARCA:XBI).

Institutional Ownership by Quarter for SPDR S&P Biotech (NYSEARCA:XBI)

Receive News & Ratings for SPDR S&P Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply